Document Detail


Elevation of cytokine levels in cachectic patients with prostate carcinoma.
MedLine Citation:
PMID:  12599227     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Approximately 60-70% of patients with advanced prostate carcinoma (CaP) suffer from cachexia, one of the most devastating conditions associated with advanced malignant disease. The pathophysiology of cachexia is multifactorial, and several cytokines, such as tumor necrosis factor alpha (TNFalpha) and interleukin 1 (IL-1), IL-6, and IL-8, may be involved. The objective of the current study was to determine whether cachexia associated with advanced CaP is accompanied by increased serum levels of TNFalpha, IL-1beta, IL-6, and IL-8. METHODS: The levels of TNFalpha, IL-1beta, IL-6, IL-8, and prostate specific antigen (PSA) were examined in serum samples from normal donors (n = 10 donors), from patients with organ-confined CaP (n = 19 patients), from patients with advanced CaP without cachexia (n = 17 patients), and from patients with cachectic CaP (n = 26 patients). DPC Immulite and Abbott IMx Total-PSA assays were used to determine cytokine and PSA levels, respectively. RESULTS: Levels of TNFalpha, IL-6, and IL-8 were elevated significantly in the group of patients with advanced, cachectic CaP compared with patients who were without cachexia. In the cachectic patients, levels of TNFalpha were correlated positively with IL-8, and there was no correlation between PSA levels and any of the cytokine levels. IL-1beta levels were below the limit of detection in all samples. CONCLUSIONS: The current results show that levels of TNFalpha, IL-6, and IL-8 were increased in CaP patients with cachexia. Increased levels of these cytokines were not correlated with PSA levels, suggesting that they are regulated by a mechanism that is independent of PSA synthesis. Additional fundamental research is needed to determine the mechanisms involved and to identify potential therapeutic targets in patients with cachexia.
Authors:
Jesco Pfitzenmaier; Robert Vessella; Celestia S Higano; Jennifer L Noteboom; David Wallace; Eva Corey
Related Documents :
11756987 - Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni.
20836727 - Relation between c-reactive protein and body mass index in patients with polycystic ova...
17255137 - Characteristics and treatment responses of patients satisfying the bsr guidelines for a...
8050197 - Tumor necrosis factor and intravenous gammaglobulins in common variable immunodeficiency.
20880177 - Distribution trends of colorectal adenoma and cancer: a colonoscopy database analysis o...
21654447 - Wilmington robotic exoskeleton: a novel device to maintain arm improvement in muscular ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Cancer     Volume:  97     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2003 Mar 
Date Detail:
Created Date:  2003-02-24     Completed Date:  2003-05-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1211-6     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2003 American Cancer Society.
Affiliation:
Department of Urology, University of Washington, Seattle, Washington 98195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Cachexia / blood*,  etiology
Cytokines / blood*
Humans
Interleukin-1 / blood
Interleukin-6 / blood
Interleukin-8 / blood
Male
Middle Aged
Prostate-Specific Antigen / blood
Prostatic Neoplasms / blood*,  complications,  radiotherapy
Tumor Necrosis Factor-alpha / metabolism
Chemical
Reg. No./Substance:
0/Cytokines; 0/Interleukin-1; 0/Interleukin-6; 0/Interleukin-8; 0/Tumor Necrosis Factor-alpha; EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding ...
Next Document:  High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for ...